- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Metastatic colorectal cancer (mCRC) occurs when the cancer cells have spread from the place where it has started (colon or rectum) to other parts of the body.
Showing all 6 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
PlGF , VEGF-A , VEGF-B |
Fusion protein |
Zaltrap® |
25 mg/mL |
– |
2 mg |
tba |
tba |
197,00 € |
||
VEGF-A |
Monoclonal Antibody |
Zirabev® |
25 mg/mL |
– |
2 mg |
tba |
tba |
200,00 € |
||
VEGF-A |
Monoclonal Antibody |
Alymsys® |
25 mg/mL |
– |
2 mg |
tba |
tba |
197,00 € |
||
VEGF-A |
Monoclonal Antibody |
Aybintio® |
25 mg/mL |
– |
2 mg |
tba |
tba |
197,00 € |
||
VEGF-A |
Monoclonal Antibody |
Abevmy® |
25 mg/mL |
– |
2 mg |
tba |
tba |
207,00 € |
||
VEGF-A |
Monoclonal Antibody |
Vegzelma® |
25 mg/mL |
– |
2 mg |
tba |
tba |
198,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany